Edesa Biotech (NASDAQ:EDSA – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.25, Zacks reports.
Edesa Biotech Stock Performance
Shares of NASDAQ:EDSA opened at $1.92 on Friday. The firm has a fifty day moving average price of $2.86 and a 200 day moving average price of $3.93. Edesa Biotech has a fifty-two week low of $1.69 and a fifty-two week high of $5.99.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of Edesa Biotech in a research note on Tuesday, August 20th.
Edesa Biotech Company Profile
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
See Also
- Five stocks we like better than Edesa Biotech
- What is a buyback in stocks? A comprehensive guide for investors
- GRAIL: Biotech Stock Targeting $100B Cancer Market
- Short Selling: How to Short a Stock
- MarketBeat Week in Review – 12/9 – 12/13
- What to Know About Investing in Penny Stocks
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
